ACCORD Company Profile

What is the competitive landscape for ACCORD, and what generic alternatives to ACCORD drugs are available?

ACCORD has one hundred and fifty-five approved drugs.

There are four US patents protecting ACCORD drugs. There are three tentative approvals on ACCORD drugs.

There are thirty-five patent family members on ACCORD drugs in eighteen countries and three hundred and eighty-six supplementary protection certificates in eighteen countries.

Summary for ACCORD

International Patents:	35
US Patents:	4
Tradenames:	132
Ingredients:	129
NDAs:	155
Patent Litigation for ACCORD:	See patent lawsuits for ACCORD
PTAB Cases with ACCORD as petitioner:	See PTAB cases with ACCORD as petitioner

Drugs and US Patents for ACCORD

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Accord Hlthcare	IBANDRONATE SODIUM	ibandronate sodium	INJECTABLE;INTRAVENOUS	206058-001	Feb 5, 2016	AP	RX	No	No
Accord Hlthcare	TEMOZOLOMIDE	temozolomide	CAPSULE;ORAL	201528-003	Feb 27, 2017	AB	RX	No	No
Accord Hlthcare	LISINOPRIL	lisinopril	TABLET;ORAL	202554-004	Jul 30, 2013	AB	RX	No	No
Accord Hlthcare	RANOLAZINE	ranolazine	TABLET, EXTENDED RELEASE;ORAL	212930-002	May 18, 2021		DISCN	No	No
Accord Hlthcare	MYCOPHENOLATE MOFETIL	mycophenolate mofetil	TABLET;ORAL	065416-001	May 4, 2009	AB	RX	No	No
Accord Hlthcare	ATROPINE SULFATE	atropine sulfate	SOLUTION;INTRAVENOUS	212868-001	Jul 26, 2021	AP	RX	No	No

Paragraph IV (Patent) Challenges for ACCORD drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	for Injection	100 mcg/vial and 500 mcg/vial		2015-04-14
	for Injection	200 mcg/vial		2015-05-01

International Patents for ACCORD Drugs

Country	Patent Number	Estimated Expiration
Israel	275448
Brazil	PI0706558
South Korea	20210005542
Russian Federation	2427383
World Intellectual Property Organization (WIPO)	2019125358
World Intellectual Property Organization (WIPO)	2007084460

Supplementary Protection Certificates for ACCORD Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1189916	C300477	Netherlands		PRODUCT NAME: REGADENOSON ALSMEDE FARMACEUTISCHE AANVAARDBARE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/10/643/001 20100906
0162036	2000C/032	Belgium		PRODUCT NAME: LEVETIRACETAM; NAT. REGISTRATION NO/DATE: EU/1/00/146/001 20000929; FIRST REGISTRATION: CH 55297 20000329
1915993	300625	Netherlands		PRODUCT NAME: COMBINATIE BEVATTENDE ALISKIREN, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, EN AMLODIPINE, OF EEN FARMACEUATISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/11/686/001-056 20110414
0740668	03C0017	France		PRODUCT NAME: TADALAFIL; REGISTRATION NO/DATE: EU/1/02/237/001-004 20021112
0347066	42/2002	Austria		PRODUCT NAME: ESCITALOPRAM UND DESSEN NICHT-TOXISCHE SAEUREADDITIONSSALZE; NAT. REGISTRATION NO/DATE: 1-24549, 1-24550, 1-24551, 1-24552 20020618; FIRST REGISTRATION: SE 17084, 17085, 17086,17087 20011207
0367141	SPC/GB04/039	United Kingdom		PRODUCT NAME: ARIPIPRAZOLE OR A SALT THEREOF; REGISTERED: UK EU/1/04/276/001 20040604; UK EU/1/04/276/002 20040604; UK EU/1/04/276/003 20040604; UK EU/1/04/276/004 20040604; UK EU/1/04/276/005 20040604; UK EU/1/04/276/006 20040604; UK EU/1/04/276/007 20040604; UK EU/1/04/276/008 20040604; UK EU/1/04/276/009 20040604; UK EU/1/04/276/010 20040604; UK EU/1/04/276/011 20040604; UK EU/1/04/276/012 20040604; UK EU/1/04/276/013 20040604; UK EU/1/04/276/014 20040604; UK EU/1/04/276/015 20040604; UK EU/1/04/276/016 20040604; UK EU/1/04/276/017 20040604; UK EU/1/04/276/018 20040604; UK EU/1/04/276/019 20040604; UK EU/1/04/276/020 20040604

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Accord
• Accord Hlthcare
• Accord Hlthcare Inc